In PeerLINC’s first year of operations it empowered eight countries to accelerate the adoption of shorter, safer, and more effective DR-TB treatments, improving lives and strengthening healthcare systems worldwide.

In February 2024, Peru became one of the first in the region to adopt the BPaLM (bedaquiline, pretomanid, linezolid, and moxifloxacin) regimen, recommended by the World Health Organization (WHO) for the treatment of drug-resistant tuberculosis. To date, 790 patients have received this regimen, while a total of 1,231 people have benefited from shortened oral treatments, achieving a better quality of life and increasing the therapeutic success rate.

A faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.

The newly inaugurated PeerLINC Knowledge Hub in Manila is poised to harness local expertise and experience to catalyze the adoption of advanced and more efficacious cures for tuberculosis (TB) on a global scale.

Once again, the Philippines is in the forefront of innovative health solutions, such that other countries like Peru, are sending health teams to observe and learn our government’s early adoption of the new drug-resistant TB treatment regimen under program conditions.

The Knowledge Hub will focus on supporting global use of new treatments that effectively treat drug-resistant TB